Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0279450 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Chalermkiat Kansuttiviwat und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Venous Thromboembolism, Thrombosis, Venous Thrombosis, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medicine, Chiang Mai University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Despite the conflicting data, the positivity of antiphospholipid antibodies (aPL) in cancer patients may be associated with an increased risk of thrombosis.
Objective
To identify the prevalence and impact of aPL on venous thromboembolic events (VTE) and arterial thrombosis (ATE) in ambulatory cancer patients Methods In this single-center, prospective cohort study, we enrolled newly diagnosed ambulatory cancer patients receiving chemotherapy. Non-cancer controls were age- and sex-matched. Participants were evaluated for aPL. Primary outcomes were the composite outcome of VTE or ATE and the prevalence of aPL positivity in cancer patients. Secondary outcomes included the risk of VTE and ATE in cancer patients and all-cause mortality at six-month follow-up duration.
Results
There were 137 cases and 137 controls with mean age of 56.0±12.3 and 55.5±12.1 years, respectively. Cancer patients were more likely to have positive aPL compared to controls, with the risk difference of 9.4% (95%CI 1.5 to 17.5). Composite of ATE or VTE occurred in 9 (6.6%) in cancer patients and 2 (1.5%) in controls. Cancer patients with aPL positivity were associated with higher risk of ATE or VTE (risk ratio [RR] 3.6, 95% CI 1.04–12.4). Positive LA in cancer patients were associated with higher risk of composites of ATE or VTE (RR 5.3 95%CI 1.3–21.0), whereas the anti-β2-GPI positivity were associated with increased risk of VTE (RR 4.7, 95%CI 1.1–19.2). Conclusion aPL was more prevalent in active cancer patients and positive aPL in cancer patients was associated with arterial or venous thrombosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Chalermkiat Kansuttiviwat, Adisak Tantiworawit, Sasinee Hantrakool, Chatree Chai-Adisaksopha
Förderung
- Faculty of Medicine, Chiang Mai University
Zitieren
APA
Kansuttiviwat, C., Niprapan, P., Tantiworawit, A., Norasetthada, L., Rattarittamrong, E., Rattanathammethee, T., Hantrakool, S., Piriyakhuntorn, P., Punnachet, T., Hantrakun, N., & Chai-Adisaksopha, C. (2023). Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0279450
Vancouver
Kansuttiviwat C, Niprapan P, Tantiworawit A, Norasetthada L, Rattarittamrong E, Rattanathammethee T, et al. Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients. PLOS ONE. 2023. doi:10.1371/journal.pone.0279450
BibTeX
@article{Kansuttiviwat2023,
author = {Kansuttiviwat, Chalermkiat and Niprapan, Piangrawee and Tantiworawit, Adisak and Norasetthada, Lalita and Rattarittamrong, Ekarat and Rattanathammethee, Thanawat and Hantrakool, Sasinee and Piriyakhuntorn, Pokpong and Punnachet, Teerachat and Hantrakun, Nonthakorn and Chai-Adisaksopha, Chatree},
title = {Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0279450}
}
EUVIMED